Quick Answer
TriSalus Life Sciences, Inc. reported Total Assets of $35.33 million for the year ending 2025.
- TriSalus Life Sciences, Inc. showed an increase of +47.4% in Total Assets from 2024 to 2025.
- This data is from TriSalus Life Sciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $251.79 million | Q2 2021: $251.21 million | Q3 2021: $250.76 million | Q1 2022: $250.40 million | Q2 2022: $250.55 million | Q3 2022: $251.33 million | Q1 2023: $20.52 million | Q2 2023: $12.24 million | Q3 2023: $33.55 million | Q1 2024: $17.89 million | Q2 2024: $32.43 million | Q3 2024: $27.48 million | Q1 2025: $28.63 million | Q2 2025: $41.32 million | Q3 2025: $36.46 million.
- Over the full 6 years of available data (2020 to 2025), TriSalus Life Sciences, Inc.'s Total Assets has declined by 86.0%.
- Historical annual values: Fiscal year 2025: $35.33 million | Fiscal year 2024: $23.97 million | Fiscal year 2023: $24.60 million | Fiscal year 2022: $22.00 million | Fiscal year 2021: $250.53 million | Fiscal year 2020: $252.01 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: